Press release
MASH Market Size in the 7MM was ~USD 1.8 billion in 2023, is projected to grow at a CAGR of 24%, estimates DelveInsight
Discover which therapies are expected to grab the MASH Market Share @ MASH Market Outlook [https://www.delveinsight.com/sample-request/metabolic-dysfunction-associated-steatohepatitis-mash-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the MASH Market Report
* In June 2025, Akero Therapeutics Inc . announced a study is to assess the safety and tolerability of EFX compared to placebo in subjects with non-invasively diagnosed NASH/MASH and NAFLD/MASLD.
* In June 2025, Boehringer Ingelheim conducted a study is to find out whether a medicine called survodutide helps people with MASH and moderate or advanced liver fibrosis improve their liver function. This study is to find out the effect of survodutide on MASH and liver fibrosis.
* In June 2025, 89bio Inc. organized a study will assess the efficacy and safety of pegozafermin administered in participants with compensated cirrhosis due to MASH (biopsy-confirmed fibrosis stage F4 MASH [previously known as nonalcoholic steatohepatitis, NASH]).
* According to DelveInsight's estimates, there were ~215 million prevalent cases of MASLD (formerly known as NAFLD) in the 7MM in 2023, including ~30 million prevalent cases of MASH. Of the total MASH cases, ~8 million were diagnosed in the 7MM.
* Among the 7MM, the US had the highest number of MASH Diagnosed Prevalent Cases, with ~4 million cases in 2023, a figure projected to increase by 2034.
* In 2023, EU4 and the UK accounted for ~3 million MASH diagnosed prevalent cases with Germany having the highest at ~780 thousand cases, followed by Italy with ~615 thousand cases. In contrast, Spain had the least, with ~340 thousand cases.
* In 2023, the UK had ~480 thousand MASH Diagnosed Prevalent Cases.
* In 2023, Japan recorded ~670 thousand MASH diagnosed prevalent cases, a number expected to rise by 2034.
* In 2023, the US had the following severity-specific diagnosed prevalent cases of MASH: ~880 thousand cases at the F0 stage, ~1,610 thousand at the F1 stage, ~880 thousand at the F2 stage, ~510 thousand at the F3 stage, and ~340 thousand at the F4 stage.
* The leading MASH Companies such as 89bio, Inc., Akero Therapeutics, Galectin Therapeutics, Viking Therapeutics, Novo Nordisk A/S, Inventiva, and others.
* Promising MASH Pipeline Therapies such as TVB-2640, Survodutide, Miricorilant (Cohort B), Efimosfermin, Pegozafermin, DD01, ALG-055009, and others.
Stay ahead in the MASH Therapeutics Market with DelveInsight's Strategic Report @ MASH Treatment Market [https://www.delveinsight.com/sample-request/metabolic-dysfunction-associated-steatohepatitis-mash-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
MASH Epidemiology Segmentation in the 7MM
* Total MASH Prevalent Cases
* Total MASH Prevalent Cases
* Total Diagnosed Prevalent Cases
* MASH Severity-specific Diagnosed Prevalent Cases
Download the report to understand which factors are driving MASH Epidemiology trends @ MASH Prevalence [https://www.delveinsight.com/sample-request/metabolic-dysfunction-associated-steatohepatitis-mash-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
MASH Marketed Drugs
* REZDIFFRA (resmetirom): Madrigal Pharmaceuticals
REZDIFFRA (resmetirom), a Thyroid Hormone Receptor-beta (THR-Ss) agonist, is approved for treating adults with noncirrhotic MASH and moderate to advanced liver fibrosis (F2-F3), in conjunction with diet and exercise. It received accelerated approval due to improvements in MASH and fibrosis. In March 2024, the US FDA approved REZDIFFRA for adults with noncirrhotic MASH with moderate to advanced liver fibrosis (F2 to F3).
MASH Emerging Drugs
* Efruxifermin (EFX): Akero Therapeutics
Efruxifermin (EFX), Akero Therapeutics' leading candidate for MASH, is an engineered Fc-FGF21 fusion protein mimicking the biological activity of native FGF21. EFX has shown promise in reducing liver fat, inflammation, and fibrosis, while enhancing insulin sensitivity and lipid metabolism. It offers once-weekly dosing and a favorable tolerability profile in clinical trials. Currently, EFX is being evaluated in three Phase III studies, with encouraging results from Phase II trials showing its potential to reverse fibrosis and improve liver function. The Phase III SYNCHRONY study is expected to provide results in 2026.
* VK2809 (TRSs Agonist): Viking Therapeutics
VK2809 is an orally available, liver-targeted agonist of the Thyroid Hormone Beta Receptor (TRSs), designed to specifically modulate lipid metabolism. By selectively activating TRSs in liver tissue, VK2809 aims to improve cholesterol and lipoprotein levels through the upregulation of genes involved in lipid clearance. The compound has shown significant therapeutic potential in lipid disorders, meeting both primary and secondary endpoints in the Phase IIb VOYAGE study for patients with NASH/MASH and fibrosis, as well as in a Phase IIa study for patients with elevated LDL-C and MASLD.
* Efimosfermin alfa (formerly BOS-580): Boston Pharmaceuticals
Efimosfermin alfa (BOS-580), developed by Boston Pharmaceuticals, is a long-acting variant of FGF21 designed to regulate metabolic pathways, reducing liver fat, inflammation, and fibrosis in MASH patients. Manufactured in mammalian cells for human-like glycosylation, it is administered as a once-monthly subcutaneous injection. BOS-580 is currently undergoing Phase II trials for MASH treatment. In September 2020, Boston Pharmaceuticals licensed the genetically engineered FGF21 variant from Novartis, positioning it as a potential best-in-class treatment for MASH.
To learn more about MASH Treatment guidelines, visit @ MASH Clinical Trials Assessment [https://www.delveinsight.com/sample-request/metabolic-dysfunction-associated-steatohepatitis-mash-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
MASH Companies
89bio, Inc., Akero Therapeutics, Galectin Therapeutics, Viking Therapeutics, Novo Nordisk A/S, Inventiva, and others.
MASH Drugs Market Insights
Efruxifermin (EFX) is an investigational Fc-FGF21 fusion protein developed by Akero Therapeutics for the treatment of MASH. Designed to mimic the biological activity of FGF21, EFX aims to address key drivers of MASH by reducing liver fat and inflammation, reversing fibrosis, and improving insulin sensitivity and lipid metabolism. In a 96-week Phase IIb study, 39% of patients with compensated cirrhosis due to MASH experienced a reversal of cirrhosis without worsening of the disease, compared to 15% in the placebo group. These promising results have led to the initiation of the Phase III SYNCHRONY clinical program, which includes trials evaluating EFX in patients with pre-cirrhotic MASH (F2-F3 fibrosis) and those with compensated cirrhosis (F4) due to MASH.
MASH Treatment Market
The MASH treatment landscape is rapidly evolving, particularly with the USFDA's accelerated approval of Madrigal's REZDIFFRA, now considered a key therapy for patients with moderate to advanced liver fibrosis. This selective thyroid hormone receptor-beta agonist has shifted the approach from invasive liver biopsies to non-invasive diagnostic methods, improving patient access to treatment. The landscape is further shaped by a diverse pipeline of therapies targeting various mechanisms, such as FXR agonists, PPAR modulators, and GLP-1 receptor agonists, with clinical trials exploring combination therapies to address the complex nature of the disease. As researchers focus on personalized medicine and better patient stratification, the priority remains refining treatment strategies while navigating challenges in trial recruitment and regulatory requirements. The combination of emerging therapies and existing lifestyle interventions continues to influence clinical practice in managing MASH/NASH.
Learn more about the FDA-approved drugs for MASH @ Drugs for MASH Treatment [https://www.delveinsight.com/sample-request/metabolic-dysfunction-associated-steatohepatitis-mash-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the MASH Market Report
* Coverage- 7MM
* Study Period- 2020-2034
* MASH Companies- 89bio, Inc., Akero Therapeutics, Galectin Therapeutics, Viking Therapeutics, Novo Nordisk A/S, Inventiva, and others.
* MASH Pipeline Therapies- TVB-2640, Survodutide, Miricorilant (Cohort B), Efimosfermin, Pegozafermin, DD01, ALG-055009, and others.
* MASH Market Dynamics: MASH Market Drivers and Barriers
* MASH Market Access and Reimbursement, Unmet Needs and Future Perspectives
Table of Contents
1. Key Insights
2. MASH Market Report Introduction
3. MASH Market Overview at a Glance
4. Methodology of Epidemiology and Market
5. Executive Summary
6. Key Events
7. Disease Background and Overview
8. MASH Epidemiology and Patient Population
9. Patient Journey
10. MASH Marketed Drugs
11. MASH Emerging Drugs
12. MASH - 7MM Market Analysis
13. Key Opinion Leaders' Views
14. MASH Unmet Needs
15. MASH SWOT Analysis
16. MASH Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=mash-market-size-in-the-7mm-was-usd-18-billion-in-2023-is-projected-to-grow-at-a-cagr-of-24-estimates-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/metabolic-dysfunction-associated-steatohepatitis-mash-market
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release MASH Market Size in the 7MM was ~USD 1.8 billion in 2023, is projected to grow at a CAGR of 24%, estimates DelveInsight here
News-ID: 4058249 • Views: …
More Releases from ABNewswire
Bedrock Restoration - Water Fire Mold Damage Service, Expands Water Damage Repai …
Water Fire Mold Damage Service, a trusted provider of property restoration, has announced expanded service offerings to meet the growing demand for professional water damage solutions in the region. Known for their reliable, customer-focused approach, the company continues to support both homeowners and businesses in recovering from unexpected property damage caused by water, fire, or mold.
Responding to a Growing Need for Water Damage Restoration
Property owners across Minnesota are increasingly seeking…
Winkler Kurtz LLP Expands Resources to Handle Increased Demand for Personal Inju …
For individuals searching for personal injury attorneys, the expansion of Winkler Kurtz LLP's team means greater accessibility and reduced wait times for consultations. The firm's deep roots in the Port Jefferson Station community allow them to understand local nuances, such as common accident hotspots and specific regional legal precedents.
Port Jefferson Station has seen a notable rise in personal injury cases, driven by factors such as increased traffic congestion, construction activity,…
Protecting Property Value: Hose Bros Inc Highlights How Professional Power Washi …
For residents searching for power washing near me, Hose Bros Inc offers accessible and reliable services tailored to the Millsboro community. Their local expertise ensures an understanding of regional challenges, such as the impact of salt air on coastal properties or the tendency for humidity to promote mold growth in shaded areas. This knowledge allows them to customize their approach, selecting appropriate pressure levels and cleaning agents for different surfaces.
In…
![Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Prices](https://cdn.open-pr.com/9/1/914818326_g.jpg)
Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Price …
A 2025 cost guide to kitchen, bathroom, and full home remodeling in Tampa Bay, featuring expert insights from Craftline Remodeling on pricing, budgeting, and contractor selection.
Market Overview: Understanding Tampa Bay Remodeling Investment Trends
Tampa Bay's home remodeling market has experienced significant cost evolution in 2025, with project expenses varying dramatically across South Tampa, Carrollwood, Seminole Heights, Clearwater, St. Petersburg, and Wesley Chapel based on material choices, project scope, and contractor expertise.…
More Releases for MASH
Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Trends, Epid …
Metabolic Dysfunction-Associated Steatohepatitis (MASH), formerly referred to as Non-Alcoholic Steatohepatitis (NASH), is a progressive form of fatty liver disease characterized by fat accumulation, inflammation, hepatocyte injury, and varying degrees of fibrosis. It is closely linked to obesity, type 2 diabetes, metabolic syndrome, and cardiovascular risk factors.
MASH/NASH is a major global health burden, with prevalence rising due to the global obesity epidemic and sedentary lifestyles. If untreated, it can progress to…
MASH Market Momentum: Late-Stage Assets Fuel Competitive Therapeutic Landscape
Metabolic Dysfunction-Associated Steatohepatitis (MASH), formerly known as Nonalcoholic Steatohepatitis (NASH), is becoming an increasingly urgent global public health issue. This progressive liver disease, characterized by fat buildup in the liver unrelated to alcohol consumption, can lead to inflammation (hepatitis), fibrosis, cirrhosis, and eventually liver cancer.
Download Strategic Sample PDF: https://datamintelligence.com/strategic-insights/sample/metabolic-dysfunction-associated-steatohepatitis-mash?ophp
Akero Therapeutics Completes Enrollment for Double-Blind Phase III SYNCHRONY Real-World Study of Efruxifermin (EFX) in Patients with Non-Invasively Diagnosed MASH or MASLD…
Pepper Mash Market Size Estimated to grow USD 0.517 Billion by 2032
Pepper Mash Market Overview
The pepper mash market is a dynamic segment of the global food industry, characterized by its rich flavor profiles and wide-ranging applications. Pepper mash, a key ingredient in the production of hot sauces, seasonings, and processed foods, has gained significant traction due to its ability to impart heat and complexity to various dishes. This blog delves into the market overview, competitive landscape, key drivers, segmentation, and regional…
Fermented Pepper Mash Market Revenue, Insights, Overview, Outlook, Analysis | Va …
Fermented Pepper Mash Market
Fermented Pepper Mash is one of the most commonly used ingredients in kitchens and hot sauce manufacturers. This product is ideal for making medium-heat hot sauces and marinades. One can add small amounts to stews, soups and pastes to give them a mild flavor. Additionally, people can create their own homemade sauce by adding garlic, onions, vinegar, sugar, lemon juice, and more ingredients.
According to new survey, global…
Pepper Mash Market Production, Consumption, Export-Import Analysis Through 2030
** Market Overview **
Pepper mash refers to a mixture of ground black peppercorns in brine, vinegar or other solutions that is used to impart flavor, spice and heat to various food products. It is used in sauces, marinades, snacks, meat products and other culinary applications across the world.
The growth of the global pepper mash market is being driven by rising demand for convenience foods, growing adoption of international cuisines and…
Mash Tun Media: New UK Marketing Agency working exclusively with breweries
Mash Tun Media, the latest and most focused Digital Marketing Agency for Microbreweries has been developed and launched by the team at Future State Media.
Developing niche-specific skills and understanding of the unique demands of the microbrewing market has been a passion of the team at Future State Media for the past year. Working in the brewing niche has aligned so well with existing successful projects where the team had…
